According to Weber & Co., “in February 2019 Marinomed Biotech successfully completed its initial public offering on the Vienna Stock Exchange. Marinomed is a biopharmaceutical company that was created in 2006 as a spin-off from the University of Veterinary Medicine Vienna and focuses on the development of innovative products in the field of respiratory and eye diseases based on patented technology platforms. Of the total 105,000 shares, 55,000 shares are sold from the intended target volume and a further 50,000 shares from the upsize alternative, which was fully utilized due to the high demand. The proceeds from the advanced bookbuilding sale for Acropora Beteiligungs, VETWIDI Forschungsholding, and BVT Beteiligungsverwaltung und Treuhand total approximately EUR 10 million."
The settlement of the Marinomed shares placed in the ABB is expected to take place on January 28, 2020. After completion of the sale, Acropora, VETWIDI, and BVT will retain approximately 16.6%, 1.5%, and 1.4% of the Marinomed share capital, respectively.
The Weber & Co. team included Partner Christoph Moser and Associate Angelika Fischer.
Herbst Kinsky's team was led by Partner Philipp Kinsky and included Associate Georg Durstberger.